Literature DB >> 10933151

Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases.

Y Maor-Kendler1, K P Batts, L J Burgart, R H Wiesner, R A Krom, C B Rosen, M R Charlton.   

Abstract

BACKGROUND: End-stage liver disease for which no cause can be identified, cryptogenic cirrhosis, is a common indication for liver transplantation. Allograft inflammation and fibrosis have been reported to recur with similar frequencies after liver transplantation for cryptogenic cirrhosis and hepatitis C (HCV).
METHODS: We determined sequential posttransplant allograft histology in four groups of recipients: 31 transplanted for cryptogenic cirrhosis, 70 for cholestatic etiologies, 40 for alcoholic liver disease, and 56 for HCV. Modified hepatitis activity index (HAI) and fibrosis stage were determined at 4 months, 1 year, and at most recent biopsy posttransplantation.
RESULTS: The prevalence of HAI > or = 2 among cryptogenic recipients was similar to that of cholestatic and alcoholic recipients at 4 months, 1 year, and at most recent evaluation (mean 45+/-17 months posttransplantation). For HCV-infected recipients, the frequency of HAI > or = 2 was more than for cryptogenic recipients at 1 year (52 vs. 29%, P=0.04) and at most recent evaluation (64 vs. 15%, P=0.003). Fibrosis scores for cryptogenic, cholestatic, and alcoholic recipients were similar at all timepoints. The proportion of HCV-infected recipients with fibrosis stage >2 was more than that of cryptogenic recipients at 4 months (29 vs. 12%, P=0.05), 1 years (46 vs. 7%, P=0.0002), and at most recent evaluation (42 vs. 15%, P=0.06). None of the cryptogenic recipients developed cirrhosis.
RESULTS: The frequency of elevated HAI and fibrosis stage in recipients who undergo transplantation for cryptogenic cirrhosis is similar to that of recipients who undergo transplantation for cholestatic etiologies and significantly less than that of HCV-infected recipients. Fibrosis stage and HAI are generally stable after transplantation for cryptogenic cirrhosis. These data do not suggest a viral etiology of liver disease in the majority of patients with cryptogenic cirrhosis.

Entities:  

Mesh:

Year:  2000        PMID: 10933151     DOI: 10.1097/00007890-200007270-00009

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

Review 1.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 2.  Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations.

Authors:  Robert J Wong; Aijaz Ahmed
Journal:  World J Hepatol       Date:  2014-05-27

Review 3.  Treatment strategies for chronic hepatitis C prior to and following liver transplantation.

Authors:  Ryan B Perumpail; Thomas A Hahambis; Avin Aggarwal; Zobair M Younossi; Aijaz Ahmed
Journal:  World J Hepatol       Date:  2016-01-08

4.  Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes.

Authors:  George Cholankeril; Robert J Wong; Menghan Hu; Ryan B Perumpail; Eric R Yoo; Puneet Puri; Zobair M Younossi; Stephen A Harrison; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2017-07-25       Impact factor: 3.199

5.  Nonalcoholic fatty liver disease following liver transplantation.

Authors:  Sanjaya Kumar Satapathy; Satheesh Nair; Jason M Vanatta
Journal:  Hepatol Int       Date:  2013-04-26       Impact factor: 6.047

6.  Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease.

Authors:  Stefano Targhetta; Federico Villamil; Paolo Inturri; Patrizia Pontisso; Stefano Fagiuoli; Umberto Cillo; Attilio Cecchetto; Simona Gianni; Remo Naccarato; Patrizia Burra
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

7.  Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report.

Authors:  Justin R Cuschieri; Bijo K John; Ronald Miick; Jorge A Ortiz; Nikroo Hashemi
Journal:  J Clin Exp Hepatol       Date:  2013-01-25

Review 8.  Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.

Authors:  Vikas Khullar; Angela Dolganiuc; Roberto J Firpi
Journal:  World J Transplant       Date:  2014-06-24

Review 9.  Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.

Authors:  Mina Shaker; Adam Tabbaa; Mazen Albeldawi; Naim Alkhouri
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 10.  Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival.

Authors:  Harmeet Malhi; Alina M Allen; Kymberly D Watt
Journal:  Curr Opin Organ Transplant       Date:  2016-04       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.